Carsten Thiel takes over at Abeona

3 April 2018

US gene therapy developer Abeona Therapeutics (Nasdaq: ABEO) has lured one of the most experienced names in rare diseases to become its new chief executive.

Carsten Thiel (pictured above), whose 25 years of biopharma experience includes spells with US drugmakers Alexion Pharmaceuticals (Nasdaq: ALXN) and Amgen (Nasdaq: AMGN), takes over in the top job from Timothy Miller, who remains president and becomes chief scientific officer of Abeona.

At Alexion, Dr Thiel was executive vice president and chief commercial officer, having also led commercial operations for certain global regions. At Amgen, his roles included head of Europe and general manager for Germany.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK